Exelixis, Inc. $EXEL Stake Lessened by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.8% in the third quarter, HoldingsChannel.com reports. The firm owned 585,082 shares of the biotechnology company’s stock after selling 16,862 shares during the period. Russell Investments Group Ltd.’s holdings in Exelixis were worth $34,177,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Eurizon Capital SGR S.p.A. bought a new position in shares of Exelixis during the 3rd quarter valued at about $357,000. Werba Rubin Papier Wealth Management acquired a new position in shares of Exelixis in the 3rd quarter worth approximately $213,000. CENTRAL TRUST Co grew its stake in shares of Exelixis by 44.9% in the 3rd quarter. CENTRAL TRUST Co now owns 784 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 243 shares during the last quarter. Maryland State Retirement & Pension System raised its holdings in shares of Exelixis by 15.6% in the 3rd quarter. Maryland State Retirement & Pension System now owns 15,157 shares of the biotechnology company’s stock worth $885,000 after purchasing an additional 2,042 shares in the last quarter. Finally, New York Life Investment Management LLC raised its holdings in shares of Exelixis by 9.9% in the 3rd quarter. New York Life Investment Management LLC now owns 32,131 shares of the biotechnology company’s stock worth $1,877,000 after purchasing an additional 2,886 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors.

Exelixis Price Performance

NASDAQ EXEL opened at $67.10 on Tuesday. The company’s fifty day moving average is $62.45 and its two-hundred day moving average is $52.35. Exelixis, Inc. has a 52-week low of $39.71 and a 52-week high of $73.69. The firm has a market capitalization of $16.37 billion, a price-to-earnings ratio of 20.09, a P/E/G ratio of 1.80 and a beta of 0.45.

Exelixis (NASDAQ:EXEL – Get Free Report) last released its earnings results on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.05. The business had revenue of $658.70 million for the quarter, compared to the consensus estimate of $646.51 million. Exelixis had a return on equity of 45.54% and a net margin of 35.45%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the business earned $0.78 earnings per share. As a group, sell-side analysts expect that Exelixis, Inc. will post 3.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on EXEL shares. William Blair reissued an “outperform” rating on shares of Exelixis in a research note on Friday, September 11th. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 9th. TD Cowen boosted their price target on shares of Exelixis from $55.00 to $76.00 and gave the company a “buy” rating in a report on Friday, October 30th. Citizens Jmp upped their target price on Exelixis from $55.00 to $65.00 and gave the stock a “market outperform” rating in a research report on Monday, October 19th. Finally, Weiss Ratings raised Exelixis from a “buy (a-)” rating to a “buy (a)” rating in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Exelixis has a consensus rating of “Hold” and an average target price of $58.62.

Read Our Latest Research Report on Exelixis

Exelixis Company Profile

(Free Report)

Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.

Further Reading

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.